Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
August 19 2024 - 8:30AM
Business Wire
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha
Cognition “ACI”, or the “Company”), a biopharmaceutical company
developing novel therapeutics for debilitating neurodegenerative
disorders, is pleased to announced the United States Patent and
Trademark Office (USPTO) has issued a Notice of Allowance for
patent application No. 18/463,157, entitled “Solid Forms of
ALPHA-1062 Gluconate,” which includes claims covering an additional
novel crystalline solid form of ZUNVEYL and complements existing
patents that the Company holds for ZUNVEYL. The patent provides
protection for a second commercially viable form of the drug. A
Notice of Allowance is issued after the USPTO makes the
determination that the claimed invention is patentable, and a
patent should be granted from an application.
This Notice of Allowance is a critical milestone in our mission
to develop transformative therapies for Alzheimer’s disease. It not
only recognizes the innovative nature of our research but also
strengthens the Company’s ability to protect the long patent life
through 2042 that ZUNVEYL has in the United States market.
"Allowance of this composition-of-matter patent, covering a
specific solid form of benzgalantamine, provides another important
layer of proprietary intellectual property protection for our lead
asset, ZUNVEYL, an FDA-approved medication for the treatment of
mild to moderate Alzheimer’s disease," said Michael McFadden, Chief
Executive Officer of Alpha Cognition. "Claims covering additional
forms of ZUNVEYL build on the patent protection the Company holds
for this product."
About Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical
company dedicated to developing treatments for patients suffering
from neurodegenerative diseases, such as Alzheimer’s disease and
Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for
which there are currently no approved treatment options.
ZUNVEYL is a patented drug approved as a new generation
acetylcholinesterase inhibitor for the treatment of Alzheimer’s
disease, with expected minimal gastrointestinal side effects.
ZUNVEYL’s active metabolite is differentiated from donepezil and
rivastigmine in that it binds neuronal nicotinic receptors, most
notably the alpha-7 subtype, which is known to have a positive
effect on cognition. ALPHA-1062 is also being developed in
combination with memantine to treat moderate to severe Alzheimer’s
dementia, and as an intranasal formulation for Cognitive Impairment
with mTBI.
Forward-looking Statements
This news release includes forward-looking statements within the
meaning of applicable United States and Canadian securities laws.
Except for statements of historical fact, any information contained
in this news release may be a forward-looking statement that
reflects the Company’s current views about future events and are
subject to known and unknown risks, uncertainties, assumptions and
other factors that may cause the actual results, levels of
activity, performance or achievements to be materially different
from the information expressed or implied by these forward-looking
statements. In some cases, you can identify forward-looking
statements by the words “may,” “might,” “will,” “could,” “would,”
“should,” “expect,” “intend,” “plan,” “objective,” “anticipate,”
“believe,” “estimate,” “predict,” “project,” “potential,” “target,”
“seek,” “contemplate,” “continue” and “ongoing,” or the negative of
these terms, or other comparable terminology intended to identify
statements about the future. Forward-looking statements may include
statements regarding the Company’s ability to obtain bridge funding
in an amount and on terms satisfactory to the Company to continue
to implement its business plan, the Company’s potential uses of any
bridge funding it does receive, the Company’s ability to adequately
implement its business plan upon receipt of bridge funding, the
Company’s ability to continue to pursue financings in the future,
the Company’s future plans to uplist to Nasdaq, the Company
continued conversations with strategic partners, the Company’s
ability to obtain alternative and non-dilutive funding, the
Company’s business strategy, market size, potential growth
opportunities, capital requirements, clinical development
activities, the timing and results of clinical trials, regulatory
submissions, potential regulatory approval and commercialization of
the Company’s products. Although the Company believes to have a
reasonable basis for each forward-looking statement, we caution you
that these statements are based on a combination of facts and
factors currently known by us and our expectations of the future,
about which we cannot be certain. The Company cannot assure that
the actual results will be consistent with these forward-looking
statements. These forward-looking statements are subject to certain
risks, including risks regarding our ability to raise sufficient
capital, including bridge funding, to implement our plans to
commercialize ZUNVEYL, risks regarding the efficacy and
tolerability of ZUNVEYL, risks related to ongoing regulatory
oversight on the safety of ZUNVEYL, risk related to market adoption
of ZUNVEYL, risks related to the Company’s intellectual property in
relation to ZUNVEYL, risks related to the commercial manufacturing,
distribution, marketing and sale of ZUNVEYL, risks related to
product liability and other risks as described in the Company’s
filings with Canadian securities regulatory authorities and
available at www.sedar.com and the Company’s filings with the
United States Securities and Exchange Commission (the “SEC”),
including those risk factors under the heading “Risk Factors” in
the Company’s Form S-1 registration statement as filed with the SEC
on June 14, 2024 and available at www.sec.gov. These
forward-looking statements speak only as of the date of this news
release and the Company undertakes no obligation to revise or
update any forward-looking statements for any reason, even if new
information becomes available in the future, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819188306/en/
Michael McFadden, CEO Tel: 1-858-344-4375
info@alphacognition.com